
Legislative roundup: Fetterman to re-introduce SMART Prices Act
May 25—WILKES-BARRE — U.S. Sen. John Fetterman, D-Pittsburgh, this week joined 26 of his colleagues to introduce the Strengthening Medicare and Reducing Taxpayer (SMART) Prices Act.
The bill, led by Sen. Amy Klobuchar (D-MN) and Sen. Peter Welch (D-VT), would expand Medicare's ability to negotiate lower drug prices for consumers, reduce federal spending, and give the Department of Health and Human Services (HHS) stronger tools to negotiate lower drug costs in Medicare Part B and Part D.
Pennsylvania seniors fill more than 100 million prescriptions every year — this bill means they'll finally get a fair shake at the pharmacy counter. In addition, taxpayers will see serious savings.
According to preliminary estimates from West Health and Verdant Research, if the SMART Prices Act were to be enacted in 2026, it would save 33% more by 2030 than current law. It would also allow Medicare to begin negotiations earlier and bring down the price of more expensive drugs.
"No one should have to choose between medicine and groceries. Multi-billion-dollar drug corporations are making obscene profits off of seniors and working families struggling just to get by," Fetterman said. "The SMART Prices Act is not complicated: it will boost Medicare's ability to negotiate fair deals with pharmaceutical companies and bring drug prices down. Big Pharma lobbyists might hate it, but regular people sure as hell won't."
This legislation builds on provision included in the Inflation Reduction Act that empowered Medicare to negotiate prescription drug prices for the first time, unleashing the power of 53 million seniors enrolled in Medicare Part D Drug Coverage.
The SMART Prices Act would extend this progress by more than doubling the number of prescription drugs Medicare must negotiate to a minimum of 50 per year, allowing the costliest prescription drugs and biologics to have negotiated prices five years after approval by the Food and Drug Administration, and by increasing the discount that Medicare is allowed to negotiate.
DCED invests more than $22.6M to help schools
Department of Community and Economic Development (DCED) Secretary Rick Siger this week announced an investment of more than $22.6 million in 74 schools across Pennsylvania through the Solar for Schools Grant Program — which is administered by DCED and funded through the Commonwealth Financing Authority (CFA).
Program grants will help schools to cover the purchase and installation of equipment, permit fees, energy storage, and utility interconnection.
"Energy is one of the top expenses for schools, which is why investments in solar energy can help to maintain long-term financial stability and improve the quality of education they offer students," Siger said. "Those savings can then be channeled into more resources for our teachers and students, and also create good-paying clean-energy jobs and job training opportunities."
School districts, intermediate units, area career and technical schools, charter schools, cyber charter schools, chartered schools for the education of the deaf or blind, community colleges, The Thaddeus Stevens College of Technology, and The Pennsylvania College of Technology were eligible to apply for the grants.
"Schools across Pennsylvania face tight budgets, and energy costs are one additional expense among a myriad of others," said Acting Secretary of Education Dr. Carrie Rowe.
Luzerne County: $400,000 to the Hanover Area School District to install solar panels to the district's high school. The district estimates the solar project will reduce its energy costs by 78%, reduce carbon emissions by approximately 100 metric tons annually, and serve as an educational tool for over 2,300 students to learn about renewable energy and its benefits.
Legislation introduced to license music therapists
Music therapists in Pennsylvania could be professionally licensed by the Commonwealth, bringing significant economic and therapeutic benefits to families and communities under new legislation introduced by state Sen. Elder Vogel, Jr., R-47, and Sen. Carolyn Comitta, D-19.
The bipartisan legislation — Senate Bill 579 — would establish a board certification exam, continuing education requirements, and a code of ethics for trained music therapists to receive professional licensure under the State Board of Social Workers, Marriage and Family Therapists, and Professional Counselors.
"For years, I have been pushing for Pennsylvania to establish state licensure for music therapists to provide another avenue for those in need of therapy services," Vogel said. "Due to not having state licensure, most patients are denied insurance coverage for this therapy and music therapists then are limited in job opportunities here in the Commonwealth and seek employment elsewhere. Patients are losing out on a beneficial health care option and Pennsylvania is losing out on family-sustaining jobs and generating economic revenue. I am happy to introduce this legislation again and continue to fight for this important treatment option for those who can truly benefit from it."
"Music therapy can be a powerful tool to promote healing, well-being, and recovery. And licensing our highly trained music therapists will not only reduce public health costs and improve access to care, but it will also boost our economy, increase tax revenue, and help create jobs," said Comitta, who serves on the Senate Education Committee.
"I'm proud to partner with Sen. Vogel on this legislation. I also want to recognize state Rep. Eddie Day Pashinski, D-Wilkes-Barre, who championed this issue in the House. I appreciate their efforts and the work of all our music therapists and advocates in communities across the Commonwealth."
Music Therapy is an evidence-based healthcare profession that can help reduce stress, anxiety, and depression, ease pain, and improve communication and social skills.
Pennsylvania is home to the largest number of higher education programs in the country for music therapy, yet professional licensure for music therapists is not currently offered in the Commonwealth.
By establishing a license for music therapy, Pennsylvania could regain approximately $7 million by retaining graduates and $135.4 million by enabling music therapists to bill appropriately, according to the Pennsylvania Music Therapy Task Force.
In addition, most insurance companies and Behavioral Health Managed Care Organizations (BH-MCOs) deny coverage to music therapists because they lack state licensure, even when they are nationally board-certified. Of Pennsylvania's 67 counties, at least 60 are blocked from reimbursed music therapy services with BH-MCOs. As a result, employers lose approximately $128,752 per music therapist, adding up to more than $93 million in lost revenue annually for Pennsylvania businesses, healthcare facilities, and therapy practices, according to the task force.
Senate Bill 579 represents a significant opportunity to retain professional talent, expand health care access, and capture substantial economic value currently forfeited to neighboring states with more developed regulatory frameworks.
Pennsylvania is currently home to more than 600 music therapists serving 49,000 residents each year. They assist clients with a variety of clinical needs, including Alzheimer's disease, autism spectrum disorders, cerebrovascular accidents (strokes), dementia, depression, developmental and intellectual differences, Parkinson's disease, post-traumatic stress disorders, terminal illnesses, traumatic brain injuries, visual impairments, and more.
Senate Bill 579 is before the Senate Consumer Affairs and Professional Licensure Committee. It is co-sponsored by 14 senators from both sides of the aisle.
There is companion legislation in the House, House Bill 563, sponsored by Pashinski.
Reach Bill O'Boyle at 570-991-6118 or on Twitter @TLBillOBoyle.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
13 minutes ago
- CBS News
2 West Covina women arrested for alleged $4.8 million hospice care fraud
The U.S. Department of Justice announced that two West Covina women were arrested Tuesday for an alleged scheme to defraud Medicare of $4.8 million with false hospice care claims. One of the women who was arrested is the owner and operator of two West Covina hospices, Golden Meadows Hospice Inc., and D'Alexandria Hospice Inc., which billed Medicare for hospice services for patients who were allegedly not terminally ill. Between Sept. 2018 and Oct. 2022, owner and operator Normita Sierra, 71, and an accomplice, Rowena Elegado, 55, collected more than $3.8 million from Medicare on false claims, the DOJ said. Sierra, of West Covina, is charged with nine counts of healthcare fraud, one count of conspiracy, and four counts of illegal remuneration for healthcare referrals. Elegado, also of West Covina, is charged with one count of conspiracy, and four counts of illegal remuneration for health care referrals. Sierra and Elegado allegedly worked together to pay marketers to recruit patients to the hospices, knowing that most of those patients had not been referred by their primary care physicians for such services. According to the DOJ, once enrolled, the fraudulent patients rarely died in hospice care and were often discharged after six months, with payouts reaching as much as $1,300 per patient each month they stayed in hospice service. Others involved in the alleged scheme include Carl Bernardo, 53, of Chino, who pleaded guilty in September 2024 to one count of receiving kickbacks in connection with a federal health care program, and Relyndo Salcedo, 60, of Fontana, a nurse practitioner who pleaded guilty on May 22 to one count of health care fraud. According to the DOJ, Salcedo was pressured to admit ineligible patients into the hospice and then exaggerated and falsified the patients' conditions to make them seem terminally ill. If convicted of the charges, Sierra would face a maximum sentence of 10 years in federal prison for each count of healthcare fraud. Sierra and Elegado would face up to five years in federal prison for the conspiracy count and up to 10 years in federal prison for each illegal kickback count. The United States Department of Health and Human Services Office of the Inspector General and the FBI investigated the matter.
Yahoo
38 minutes ago
- Yahoo
HHS ends Biden-era COVID-19 testing program that bled taxpayers years after pandemic
FIRST ON FOX: The Department of Health and Human Services announced it is shuttering a nationwide program that offered free COVID-19 tests to community organizations, citing it bled taxpayer funds despite the pandemic's end. "With COVID-19 behaving more like the seasonal flu — rising and falling through the year — and tests widely available at retail stores nationwide, continued federal distribution is a significant waste of taxpayers' dollars," HHS told Fox News Digital Tuesday. "The COVID-19 pandemic is over and HHS is prioritizing funding projects that will deliver on President Trump's mandate to address the chronic disease epidemic and Make America Healthy Again." The government had spent more than $1 billion on the program since it was established in 2021 under the Biden administration, Fox News Digital learned. The program deployed government-purchased COVID-19 tests to community partners across the country to deliver tests at no cost to the patient. HHS cited that testing for COVID-19 now mimics seasonal flu cases, with retail shops across the country stocking their shelves with COVID tests, meaning "continued federal distribution is a significant waste of taxpayers' dollars." Doctors Warn Of 'Trifecta' Of Chronic Illnesses Plaguing Americans After Maha Report Americans who ordered tests through community partnership by 5 p.m. May 30 will still receive their order, according to HHS. Read On The Fox News App HHS is in the midst of purchasing one million newer tests that are able to differentiate between the COVID-19 virus versus the flu, which will be deployed if there are any shortfalls or emergencies with the COVID testing, Fox Digital learned. State or local health departments, as well as community organizations that have a stockpile of tests and various local health centers may still provide free tests to Americans as the program shutters, according to HHS. The COVID-19 pandemic, which tore across the country in 2020, officially ended years ago. Then-President Joe Biden declared the pandemic was "over" back in 2022, while the World Health Organization determined the pandemic officially ended by 2023. The announcement comes as the Trump administration's top health department re-focuses its direction to addressing the nation's spiraling chronic health issues, which come in the form of health issues such as rampant obesity, spikes in autism diagnoses and teenage depression. Rfk Jr's Highly Anticipated Maha Report Paints Dismal State Of Child Health, National Security Concerns President Donald Trump's Make America Healthy Again Commission, which is chaired by HHS chief Robert F. Kennedy Jr, released its anticipated report assessing chronic diseases that have gripped U.S. youth in recent years May 22. The report's findings include teenage depression nearly doubling from 2009 to 2019, more than one-in-five children over the age of six being considered obese, one-in-31 children diagnosed with autism by age 8 and childhood cancer spiking by 40% since 1975. Trump And A Healthier America Welcomed By Doctors: 'New Golden Age' "Over 40% of the roughly 73 million children (aged 0-17) in the United States have at least one chronic health condition, according to the CDC, such as asthma, allergies, obesity, autoimmune diseases, or behavioral disorders," the report stated. "Although estimates vary depending on the conditions included, all studies show an alarming increase over time." Chronic diseases have a chilling effect on national security, commission members said in a Thursday morning phone call with the media. Roughly 75% of America's youth aged 17–24 do not qualify to serve in the military due to obesity, asthma, allergies, autoimmune diseases or behavioral disorders, they said. "We now have the most obese, depressed, disabled, medicated population in the history of the world, and we cannot keep going down the same road," Food and Drug Commissioner Marty Makary said in the phone call with the media. "So this is an amazing day. I hope this marks the grand pivot from a system that is entirely reactionary to a system that will now be proactive." The MAHA report will be followed by a policy recommendation report for the federal government later this article source: HHS ends Biden-era COVID-19 testing program that bled taxpayers years after pandemic


Forbes
an hour ago
- Forbes
Access To Abortion Pill Mifepristone Could Be Threatened, Again
In this photo illustration, packages of mifepristone tablets are displayed at a family planning ... More clinic. Mifepristone is part of a two-drug regimen to induce an abortion in the first trimester of pregnancy in combination with the drug misoprostol. (Photo illustration by) The abortion pill mifepristone is in the crosshairs of politics again, as plaintiffs in several high-profile court cases together with Republican lawmakers push for restrictions. More importantly perhaps, the Food and Drug Administration is reviewing the regulation and labeling of mifepristone, a drug with a well-established safety and effectiveness record. In an unusual move, Secretary of Health and Human Services, Robert F. Kennedy Jr., issued a statement last month to the Senate Health, Education, Labor and Pensions Committee directing the FDA to 'do a complete review' of its regulations on mifepristone, a medication used in conjunction with misoprostol in two-thirds of abortions in the United States– which has been used by more than eight million people since its approval more than two decades ago. The FDA approved mifepristone in 2000 for medication abortion. Mifepristone is a drug that blocks progesterone, which is needed for a pregnancy to continue. When taken in conjunction with misoprostol, mifepristone ends early pregnancies (up to ten weeks following conception). Mifepristone can be safely administered at home when prescribed by a provider, The FDA has allowed people to take the medication outside of a clinic setting since 2021. And that same year, the FDA further eased several conditions with respect to the prescribing and sale of mifepristone. Specifically, the regulatory authority allowed for prescriptions to be issued through telemedicine visits in addition to shipments of the product by mail, as MedPage Today reported. It appears that rising numbers of abortions using prescription drugs in the past four years may be linked to the changes instituted by the FDA. In addition, the use of medication to end pregnancies could have also been triggered by the Supreme Court decision to overturn Roe v. Wade in 2022, as a Journal of the American Medical Association study describes. But it appears that besides wanting to subject mifepristone to a new FDA review, Kennedy also wishes to reinstate the in-person dispensing requirement, which would mean women must go to a clinic to obtain mifepristone. The Supreme Court preserved convenient access to mifepristone last year, throwing out a lawsuit that sought to reinstate the previous requirements. The justices' argument, however, largely hinged on questioning the physician plaintiffs' right to sue the FDA to restore conditions rather than the substance of the case. But then, earlier this year, The Hill reported that a Texas federal judge, Matthew Kacsmaryk, is allowing three Republican-led states to move forward with a lawsuit to restrict access to mifepristone. It's noteworthy that in 2023, Kacsmaryk temporarily halted FDA's approval of mifepristone altogether. In brief, it's unclear what will happen to access as cases move through the court system and findings from the review which Kennedy ordered are revealed. Mifepristone has been in use in Europe for nearly three decades with a minimal number of reported adverse events. And the drug has had a similar safety record in the U.S since its approval in 2000. Between September 2000 and December 2018, only 24 of the more than 3.7 million women who had undergone medicated abortions have died, according to the FDA. Overall, the adverse events rate is less than 1% and the drug is considered safer than, say, over-the-counter non-steroidal anti-inflammatory drugs and anti-histamines. At least 100 studies from around the world have examined the effectiveness and safety of mifepristone and misoprostol. All peer-reviewed studies concluded that the pills are a safe method for terminating a pregnancy. Yet there seems to be a non-peer-reviewed study that's at the center of a request for the FDA to assess mifepristone. It's from the conservative think tank, the Ethics and Public Policy Center. This particular study makes claims about what it views as a high rate of serious adverse events following medication abortions. Yet, the evidence from the U.S. and around the globe suggests a highly safe and effective medication. The FDA's mandate is to review the safety and efficacy of drugs based on clinical evidence. As such, the FDA is the federal authority for all pharmaceuticals distributed throughout the U.S., including mifepristone and misoprostol. And so, a series of court cases and Secretary Kennedy's request for another look at mifepristone set a potentially unsettling precedent in which the FDA's regulatory authority from past decisions is undermined. And it's not just mifepristone that's currently under renewed scrutiny. Consider, for example, that HHS is revisiting debunked theories of links between the measles, mumps and rubella vaccine and autism. The department has also spearheaded changes in COVID-19 vaccine recommendations that are not necessarily evidence-based, and inconsistent with prior and even current guidance from the Centers for Disease Control and Prevention.